PepGen
Update in progressPEPG (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
PepGen Inc. is a clinical-stage biotechnology company focused on developing oligonucleotide therapeutics for severe neuromuscular and neurologic diseases in the United States. Its lead programs include PGN-EDODM1, an EDO peptide–conjugated PMO in Phase 2 for myotonic dystrophy type 1, and FREEDOM2‑DM1, also in Phase 2 for DM1. The FREEDOM-OLE open-label expansion is another program. Founded in 2018, PepGen is based in Boston, Massachusetts.
Company score
- Sentiment
- -0.18
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- -0.07
- Governance
- -0.14
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- -0.05
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- -0.11
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGS (NMS)
- LocationUnited States
- CEODr. James G. McArthur Ph.D.
- Founded2018
- Employees57
- Websitewww.pepgen.com
Identifiers
- ISINUS7133171055
- FIGIBBG012232618
- CUSIP713317105
- CIK0001835597